Boehringer Ingelheim has exercised an option for exclusive rights to an oncology target from its discovery collaboration with Oxford BioTherapeutics. The target was discovered using Oxford’s OGAP system, which incorporates one of the world’s largest proteomic databases, integrating clinical, experimental and expression data.     This represents the second option exercised under the companies’ oncology target discovery and validation collaboration established in 2013. Under th...